ILMN:NGS-Illumina Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 117.7

Change

-4.65 (-3.80)%

Market Cap

USD 19.79B

Volume

1.82M

Analyst Target

USD 347.86
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Illumina Inc provides sequencing-and array-based solutions for genetic analysis. Its products enabled researchers to explore DNA, helping them create the first map of gene variations associated with health, disease, and drug response.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-02 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

N/A

USD 38.79B
ICLR ICON PLC

N/A

USD 25.88B
NTRA Natera Inc

N/A

USD 14.01B
EXAS EXACT Sciences Corporation

N/A

USD 11.40B
MEDP Medpace Holdings Inc

N/A

USD 10.76B
RDNT RadNet Inc

N/A

USD 4.64B
SHC Sotera Health Co

N/A

USD 4.37B
NEOG Neogen Corporation

N/A

USD 3.49B
GH Guardant Health Inc

N/A

USD 3.00B
MYGN Myriad Genetics Inc

N/A

USD 2.49B

ETFs Containing ILMN

CURG:LSE VanEck Genomics and Healt.. 6.64 % 0.00 %

N/A

USD 6.97M
CURE:XETRA VanEck Genomics and Healt.. 5.36 % 0.00 %

N/A

N/A
EDOC:LSE Global X Telemedicine & D.. 4.14 % 0.00 %

N/A

USD 3.76M
EDOG:LSE Global X Telemedicine & D.. 4.14 % 0.00 %

N/A

USD 0.23M
XGES:LSE Xtrackers MSCI Genomic He.. 4.12 % 0.00 %

N/A

N/A
XGEN:XETRA Xtrackers MSCI Genomic He.. 3.84 % 0.00 %

N/A

N/A
CDNA:CA 2.74 % 0.00 %

N/A

N/A
ROBT First Trust Nasdaq Artifi.. 2.27 % 0.65 %

N/A

USD 0.42B
SAGP The Advisorsa Inner Circl.. 2.12 % 0.00 %

N/A

USD 0.04B
QQXT First Trust NASDAQ-100 Ex.. 2.06 % 0.60 %

N/A

USD 0.13B
HTEC Robo Global® Healthcare .. 1.87 % 0.00 %

N/A

USD 0.06B
DOCG:LSE L&G Healthcare Breakthrou.. 1.86 % 0.00 %

N/A

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.86 % 0.00 %

N/A

USD 0.07B
ROBO Robo Global® Robotics an.. 1.83 % 0.00 %

N/A

USD 1.12B
ROBO Robo Global® Robotics an.. 1.83 % 0.95 %

N/A

USD 1.12B
XMLH:F Legal & General Ucits Etf.. 1.77 % 0.00 %

N/A

USD 0.07B
DOCT:SW L&G Healthcare Breakthrou.. 1.77 % 0.00 %

N/A

USD 0.07B
BTEC:SW iShares Nasdaq US Biotech.. 1.73 % 0.00 %

N/A

N/A
ROBO:AU ETFS ROBO Global Robotics.. 1.71 % 0.00 %

N/A

USD 0.23B
ROBO:SW L&G ROBO Global Robotics .. 1.70 % 0.00 %

N/A

N/A
IJJ iShares S&P Mid-Cap 400 V.. 1.52 % 0.25 %

N/A

USD 7.76B
EQUL IndexIQ ETF Trust - IQ En.. 1.51 % 0.00 %

N/A

USD 7.22M
QQQE Direxion NASDAQ-100 Equal.. 1.25 % 0.35 %

N/A

USD 1.35B
QQEW First Trust NASDAQ-100 Eq.. 1.23 % 0.60 %

N/A

USD 1.93B
QQEQ:CA Invesco NASDAQ 100 Equal .. 1.16 % 0.00 %

N/A

CAD 9.99M
SPMD SPDR Russell Small Cap Co.. 0.75 % 0.06 %

N/A

USD 10.60B
IJH iShares Core S&P Mid-Cap .. 0.74 % 0.07 %

N/A

USD 89.08B
ZMID-F:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

CAD 2.03M
ZMID-U:CA BMO S&P US Mid Cap Index .. 0.70 % 0.00 %

N/A

N/A
MDY SPDR® S&P MIDCAP 400 ETF.. 0.69 % 0.24 %

N/A

USD 22.56B
SPY4:SW SPDR® S&P 400 US Mid Cap.. 0.69 % 0.00 %

N/A

USD 2.08B
SPX4:LSE SPDR® S&P 400 US Mid Cap.. 0.62 % 0.00 %

N/A

N/A
MVV ProShares Ultra MidCap400 0.58 % 0.95 %

N/A

USD 0.14B
UMDD ProShares UltraPro MidCap.. 0.42 % 0.95 %

N/A

USD 0.03B
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 1.65B
ALFA 0.00 % 0.65 %

N/A

N/A
BBH VanEck Biotech ETF 0.00 % 0.35 %

N/A

USD 0.45B
BIB ProShares Ultra Nasdaq Bi.. 0.00 % 0.95 %

N/A

USD 0.09B
BIS ProShares UltraShort Nasd.. 0.00 % 0.95 %

N/A

USD 3.31M
IBB iShares Biotechnology ETF 0.00 % 0.47 %

N/A

USD 7.71B
IBCE 0.00 % 0.10 %

N/A

N/A
IBDD 0.00 % 0.10 %

N/A

N/A
IVOO Vanguard S&P Mid-Cap 400 .. 0.00 % 0.15 %

N/A

USD 2.16B
IVOV Vanguard S&P Mid-Cap 400 .. 0.00 % 0.20 %

N/A

USD 0.92B
MDYV SPDR® S&P 400 Mid Cap Va.. 0.00 % 0.15 %

N/A

N/A
PBE Invesco Dynamic Biotechno.. 0.00 % 0.57 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
ZBIO 0.00 % 0.95 %

N/A

N/A
ROBE:LSE L&G ROBO Global Robotics .. 0.00 % 0.00 %

N/A

USD 0.75B
ROBG:LSE L&G ROBO Global Robotics .. 0.00 % 0.00 %

N/A

USD 0.75B
ROBO:LSE Legal & General UCITS ETF.. 0.00 % 0.00 %

N/A

USD 0.75B
SPY4:LSE SPDR® S&P 400 US Mid Cap.. 0.00 % 0.00 %

N/A

N/A
SPY4:PA SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

USD 2.15B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
SPY4:F SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

N/A
2B70:XETRA iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

USD 0.52B
2B78:XETRA iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

USD 1.14B
IROB:XETRA L&G ROBO Global Robotics .. 0.00 % 0.00 %

N/A

USD 0.91B
SPY4:XETRA SSgA SPDR S&P 400 US Mid .. 0.00 % 0.00 %

N/A

USD 1.99B
ZMID:CA BMO S&P US Mid Cap Index .. 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA L&G Healthcare Breakthrou.. 0.00 % 0.00 %

N/A

USD 0.07B
EDOC Global X Telemedicine & D.. 0.00 % 0.00 %

N/A

USD 0.04B
FBT:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 7.81M
FBTU:LSE First Trust Global Funds .. 0.00 % 0.00 %

N/A

USD 7.81M
BBIG:CA 0.00 % 0.00 %

N/A

N/A
IBBQ Invesco Nasdaq Biotechnol.. 0.00 % 0.00 %

N/A

USD 0.04B
2B78:F iShares Healthcare Innova.. 0.00 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.47% 51% F 34% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.47% 51% F 33% F
Trailing 12 Months  
Capital Gain -37.28% 40% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -37.28% 40% F 27% F
Trailing 5 Years  
Capital Gain -60.42% 40% F 23% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -60.42% 40% F 22% F
Average Annual (5 Year Horizon)  
Capital Gain -13.92% 36% F 23% F
Dividend Return -13.92% 36% F 23% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 33.80% 84% B 55% F
Risk Adjusted Return -41.18% 34% F 23% F
Market Capitalization 19.79B 95% A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 45.90 17% 11%
Price/Book Ratio 3.52 38% 30%
Price / Cash Flow Ratio 40.94 12% 7%
Price/Free Cash Flow Ratio -35.27 95% 93%
Management Effectiveness  
Return on Equity -20.76% 70% 44%
Return on Invested Capital -13.44% 67% 37%
Return on Assets -0.50% 83% 57%
Debt to Equity Ratio 25.92% 68% 56%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector